Long et al. identified that miR-26a expression is elevated in CTLs responding to tumor microenvironment secretome stimulation, miR-26a inhibits EZH2 to impair CTL function, indicating miR-26a-EZH2 axis as a novel target to improve the efficacy of CTL-based cancer immunotherapy [42]. This evidence concerns the gene EZH2 and neoplasm.